DexCom Inc. (NASDAQ: DXCM) stock jumped 0.90% on Wednesday to $116.73 against a previous-day closing price of $115.69. With 1.7 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.14 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $117.06 whereas the lowest price it dropped to was $114.31. The 52-week range on DXCM shows that it touched its highest point at $126.44 and its lowest point at $66.89 during that stretch. It currently has a 1-year price target of $140.32. Beta for the stock currently stands at 1.15.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DXCM was down-trending over the past week, with a drop of -1.57%, but this was down by -5.83% over a month. Three-month performance surged to 4.34% while six-month performance rose 3.61%. The stock gained 44.15% in the past year, while it has gained 3.08% so far this year. A look at the trailing 12-month EPS for DXCM yields 0.69 with Next year EPS estimates of 1.50. For the next quarter, that number is 0.23. This implies an EPS growth rate of 57.80% for this year and 37.47% for next year. EPS is expected to grow by 19.20% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 37.80%.
Float and Shares Shorts:
At present, 386.70 million DXCM shares are outstanding with a float of 384.65 million shares on hand for trading. On Apr 27, 2023, short shares totaled 12.73 million, which was 3.28% higher than short shares on Mar 30, 2023. In addition to Mr. Kevin Ronald Sayer as the firm’s Exec. Chairman, CEO & Pres, Mr. Jereme M. Sylvain serves as its Exec. VP, CFO & Chief Accounting Officer.
Institutional Ownership:
Through their ownership of 100.06% of DXCM’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 60.26% of DXCM, in contrast to 37.84% held by mutual funds. Shares owned by individuals account for 3.39%. As the largest shareholder in DXCM with 10.99% of the stake, The Vanguard Group, Inc. holds 42,465,389 shares worth 42,465,389. A second-largest stockholder of DXCM, BlackRock Fund Advisors, holds 21,099,878 shares, controlling over 5.46% of the firm’s shares. Baillie Gifford & Co. is the third largest shareholder in DXCM, holding 17,157,499 shares or 4.44% stake. With a 3.11% stake in DXCM, the Vanguard Total Stock Market ETF is the largest stakeholder. A total of 12,010,219 shares are owned by the mutual fund manager. The Vanguard 500 Index Fund, which owns about 2.35% of DXCM stock, is the second-largest Mutual Fund holder. It holds 9,069,776 shares valued at 1.1 billion. Vanguard Mid Cap Index Fund holds 2.33% of the stake in DXCM, owning 9,018,695 shares worth 1.09 billion.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on Mar 30, 2023, DXCM reported revenue of $696.20M and operating income of $77.00M. The EBITDA in the recently reported quarter was $123.60M and diluted EPS was $0.12.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DXCM since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With DXCM analysts setting a high price target of $150.00 and a low target of $115.00, the average target price over the next 12 months is $140.81. Based on these targets, DXCM could surge 28.5% to reach the target high and fall by -1.48% to reach the target low. Reaching the average price target will result in a growth of 20.63% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy.
Summary of Insider Activity:
Insiders traded DXCM stock several times over the past three months with 13 Buys and 56 Sells. In these transactions, 317,012 shares were bought while 282,929 shares were sold. The number of buy transactions has increased to 16 while that of sell transactions has risen to 73 over the past year. The total number of shares bought during that period was 443,232 while 423,247 shares were sold.
